Hepatology International

, 3:544 | Cite as

Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C

  • Takahisa Sato
  • Ryosuke Tateishi
  • Haruhiko YoshidaEmail author
  • Takamasa Ohki
  • Ryota Masuzaki
  • Jun Imamura
  • Tadashi Goto
  • Fumihiko Kanai
  • Shuntaro Obi
  • Naoya Kato
  • Shuichiro Shiina
  • Takao Kawabe
  • Masao Omata
Original Article


Background and aims

Ultrasonography is the most frequently used modality in surveillance for HCC among patients with chronic hepatitis C. However, the optimal surveillance interval is still controversial and the usefulness of supplementary tumor marker determination has not been confirmed.


A total of 243 cases of naive HCC were detected among 1,431 patients with chronic hepatitis C under outpatient-based surveillance. The mode of HCC detection, including ultrasound surveillance interval, was retrospectively examined and the relation between the interval and detected tumor size was analyzed. Tumor volume doubling time was estimated from exponential increase in serum tumor marker levels when applicable.


HCC was first detected by ultrasonography in 221 patients. Ultrasound surveillance interval, ranging between 2 and 8 months, was not correlated with the size of tumor at detection. Patients with cirrhosis were likely to be surveyed at shorter intervals. The size of tumor exceeded 30 mm only in three (1.4%) cases. They were all positive for a biomarker and the estimated tumor doubling time was short. In 14 cases, HCC was first detected by CT indicated by abnormal rise in tumor marker levels despite negative ultrasound findings. In the remaining eight cases, ultrasonography had been replaced by CT as surveillance modality because of excessive obesity or coarseness of liver parenchyma.


Ultrasound surveillance at 6-month intervals was appropriate in general for the detection of HCC at a size smaller than 30 mm. However, in patient with established cirrhosis, more frequent screening would be needed to detect tumors of the same size.


Hepatocellular carcinoma Hepatitis C Surveillance Ultrasound Tumor marker Doubling time Size of tumor Surveillance interval 





Computed tomography


Des-γ-carboxy prothrombin


HBV surface antigen


Hepatocellular carcinoma


Magnetic resonance imaging


  1. 1.
    Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. Lyon (France): IARC Scientific Publications; 2002. (Publication No.: 155)Google Scholar
  2. 2.
    Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5–S16CrossRefPubMedGoogle Scholar
  3. 3.
    Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007;102:1661–1670. (Quiz 1660, 1671)CrossRefPubMedGoogle Scholar
  4. 4.
    Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004;127:S17–S26CrossRefPubMedGoogle Scholar
  5. 5.
    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174–181PubMedGoogle Scholar
  6. 6.
    Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995;22:1027–1033CrossRefPubMedGoogle Scholar
  7. 7.
    Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003;157:674–682CrossRefPubMedGoogle Scholar
  8. 8.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236CrossRefPubMedGoogle Scholar
  9. 9.
    Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330–335CrossRefPubMedGoogle Scholar
  10. 10.
    Solmi L, Primerano AM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol 1996;91:1189–1194PubMedGoogle Scholar
  11. 11.
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417–422PubMedGoogle Scholar
  12. 12.
    Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122–130CrossRefPubMedGoogle Scholar
  13. 13.
    Chan AC, Poon RT, Ng KK, Lo CM, Fan ST, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg 2008;247:666–673CrossRefPubMedGoogle Scholar
  14. 14.
    Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251–259CrossRefPubMedGoogle Scholar
  15. 15.
    Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37–51CrossRefPubMedGoogle Scholar
  16. 16.
    Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:459–464CrossRefPubMedGoogle Scholar
  17. 17.
    Torzilli G, Minagawa M, Takayama T, Inoue K, Hui AM, Kubota K, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999;30:889–893CrossRefPubMedGoogle Scholar
  18. 18.
    Nino-Murcia M, Olcott EW, Jeffrey RB Jr, Lamm RL, Beaulieu CF, Jain KA. Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT. Radiology 2000;215:746–751PubMedGoogle Scholar
  19. 19.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–1520CrossRefPubMedGoogle Scholar
  20. 20.
    Ramirez ML, Nelson EC, Devere White RW, Lara PN Jr, Evans CP. Current applications for prostate-specific antigen doubling time. Eur Urol 2008;54:291–300CrossRefPubMedGoogle Scholar
  21. 21.
    Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086–1092CrossRefPubMedGoogle Scholar
  22. 22.
    Kim YS, Lim HK, Rhim H, Lee WJ, Joh JW, Park CK. Recurrence of hepatocellular carcinoma after liver transplantation: patterns and prognostic factors based on clinical and radiologic features. AJR Am J Roentgenol 2007;189:352–358CrossRefPubMedGoogle Scholar
  23. 23.
    Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259–266PubMedGoogle Scholar
  24. 24.
    Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology 1986;90:289–298PubMedGoogle Scholar
  25. 25.
    Okazaki N, Yoshino M, Yoshida T, Suzuki M, Moriyama N, Takayasu K, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer 1989;63:2207–2210CrossRefPubMedGoogle Scholar
  26. 26.
    Cucchetti A, Vivarelli M, Piscaglia F, Nardo B, Montalti R, Grazi GL, et al. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 2005;43:310–316CrossRefPubMedGoogle Scholar
  27. 27.
    Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001;34:603–605CrossRefPubMedGoogle Scholar
  28. 28.
    Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570–575CrossRefPubMedGoogle Scholar
  29. 29.
    Kuwahara T, Sakai T, Majima Y, Hirai K, Tanikawa K. Serial changes in serum alpha-fetoprotein prior to detection of hepatocellular carcinoma in liver cirrhosis. Hepatogastroenterology 1993;40:347–351PubMedGoogle Scholar
  30. 30.
    Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernandez-Pedro N. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer 2007;7:28CrossRefPubMedGoogle Scholar
  31. 31.
    Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006;101:524–532CrossRefPubMedGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2009

Authors and Affiliations

  • Takahisa Sato
    • 1
  • Ryosuke Tateishi
    • 1
  • Haruhiko Yoshida
    • 1
    Email author
  • Takamasa Ohki
    • 1
  • Ryota Masuzaki
    • 1
  • Jun Imamura
    • 1
  • Tadashi Goto
    • 1
  • Fumihiko Kanai
    • 1
  • Shuntaro Obi
    • 1
  • Naoya Kato
    • 1
  • Shuichiro Shiina
    • 1
  • Takao Kawabe
    • 1
  • Masao Omata
    • 1
  1. 1.Department of GastroenterologyUniversity of TokyoTokyoJapan

Personalised recommendations